

**TABLE OF CONTENTS**

TABLE OF AUTHORITIES. . . . .ii

INTRODUCTION . . . . . 1

I. INTEREST AND EXPERTISE OF THE FEDERAL TRADE COMMISSION . . 1

II. BACKGROUND . . . . . 4

    A. Generic Drug Entry Into the Marketplace . . . . . 4

    B. Hatch-Waxman Act . . . . . 6

III. POTENTIAL COMPETITIVE IMPACT OF THE PROPOSED SETTLEMENT 10

IV. CONCLUSION . . . . . 13

**TABLE OF AUTHORITIES**

| <b>CASES</b>   | <b>PAGE</b> |
|--|-------------|
| <i>Abbott Laboratories v. Novopharm Ltd.</i> ,<br>104 F.3d 1305 (Fed. Cir. 1997) .....                           | 9           |
| <i>Ben Venue Laboratories, Inc. v. Novartis Pharmaceutical Corp.</i> ,<br>10 F. Supp. 2d 446 (D.N.J. 1998) ..... | 7, 9, 10    |
| <i>Bristol-Myers Squibb Co. v. Ben Venue Laboratories</i> ,<br>90 F. Supp. 2d 522 (D.N.J. 2000) .....            | 6           |
| <i>Ciba-Geigy, Ltd.</i> ,<br>123 F.T.C. 842 (1997) .....   | 2           |
| <i>FTC v. Mylan Laboratories, Inc. et al</i> ,<br>1999-2 Trade Cas. (CCH) ¶72,573 (D.D.C. 1999) .....            | 2           |
| <i>Geneva Pharmaceuticals, Inc.</i> , C-3946 (May 26, 2000)<br>(FTC consent order) .....                         | 4           |
| <i>Hoechst AG</i> ,<br>120 F.T.C. 1010 (1995) .....  | 2           |
| <i>Purdue Pharma. L.P. v. Boehringer Ingelheim, GmbH</i> ,<br>2000 Lexis 6563 (S.D.N.Y. 2000) .....              | 9           |
| <i>Rite-Hite Corp. v. Kelley Co.</i> ,<br>56 F.3d 1538 (Fed. Cir. 1995) .....                                    | 8           |
| <i>Roche Holding Ltd.</i> , C-3809 (February 25, 1998)<br>(FTC consent order) .....                              | 2           |
| <br><b>FEDERAL STATUTES</b>  |             |
| <i>FTC Trade Commission Act</i><br><br>15 U.S.C. § 45 .....  | 1           |
| <i>Food and Drug Administration</i><br><br>21 U.S.C. § 355(a) .....  | 6           |
| 21 U.S.C. § 355(b)(1) .....  | 7           |

|                                    |    |
|------------------------------------|----|
| 21 U.S.C. § 355(c)(2) .....        | 10 |
| 21 U.S.C. § 355(j)(5)(B)(iv) ..... | 3  |
| Patent                             |    |
| 35 U.S.C. § 271(e)(1) .....        | 8  |

**REGULATIONS**

|                             |       |
|-----------------------------|-------|
| 21 C.F.R. § 314.53(b) ..... | 7, 10 |
| 21 C.F.R. § 314.53(f) ..... | 10    |
| 21 C.F.R. § 314.94 .....    | 8     |

**MISCELLANEOUS**

|   |    |
|---|----|
| Congressional Budget Office, <i>How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry</i> (July 1998) ..... | 5  |
| David A. Balto & James Mongoven, Antitrust <i>Ä</i> in Pharmaceutical Industry Mergers, 54 <i>Food &amp; Drug Law Journal</i> , 255 (1999) .....                  | 2  |
| Elizabeth Dickinson, "FDA's Role in Making Exclusivity Determinations," 54 <i>Food &amp; Drug L.J.</i> , 195, 196 (1999) ...                                      | 10 |